Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 8Genitourinary 2Thoracic 1Sarcoma 1Other hematologic neoplasm 1Dermatologic 1

Conditions

Prostatic Neoplasms 2

Interventions

Docetaxel 191Gemcitabine 148Prednisone 142pembrolizumab 125enzalutamide 119Abiraterone Acetate 108Nivolumab 107Cisplatin 103Magnetic Resonance Spectroscopy 100Radiotherapy 95Sunitinib 94Leuprolide 91Carboplatin 82Specimen Handling 71Androgen Antagonists 63bicalutamide 60Radiosurgery 60Paclitaxel 59Goserelin 59Ipilimumab 57Bevacizumab 57apalutamide 53Sorafenib 53acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 51Everolimus 49cabozantinib 48abiraterone 46atezolizumab 45cabazitaxel 43durvalumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Cilengitide × Genitourinary × Clear all
NCT00121238 2016-04-28

Cilengitide in Treating Patients With Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Completed
16 enrolled 10 charts
Genitourinary

Prostatic Neoplasms

NCT00103337 2013-02-28

Cilengitide in Treating Patients With Metastatic Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Completed
106 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡